Home Tools
Log in
Cart

Foretinib

Catalog No. T3113   CAS 849217-64-7
Synonyms: GSK089, EXEL-2880, GSK1363089, XL880

Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.

All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
Foretinib Chemical Structure
Foretinib, CAS 849217-64-7
Pack Size Availability Price/USD Quantity
2 mg In stock $ 33.00
5 mg In stock $ 52.00
10 mg In stock $ 72.00
25 mg In stock $ 135.00
50 mg In stock $ 217.00
100 mg In stock $ 373.00
500 mg In stock $ 893.00
1 mL * 10 mM (in DMSO) In stock $ 72.00
Bulk Inquiry
Get quote
Select Batch  
Purity: 99.7%
Purity: 98.07%
Contact us for more batch information
Biological Description
Chemical Properties
Storage & Solubility Information
Description Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
Targets&IC50 FLT4:2.8 nM (cell free), FLT3:3.6 nM (cell free), RON:3 nM (cell free), Tie2:1.1 nM (cell free), KDR:0.86 nM (cell free), MET:0.4 nM (cell free)
In vitro Foretinib (EXEL-2880) inhibits HGF receptor family tyrosine kinases with IC50 values of 0.4 nmol/L for Met and 3 nmol/L for Ron. EXEL-2880 also inhibits KDR, Flt-1, and Flt-4 with IC50 values of 0.9, 6.8, and 2.8 nmol/L, respectively. EXEL-2880 is a potent inhibitor of cellular Met with IC50 values of 23 and 21 nmol/L, respectively, in PC-3 prostate cells and murine B16F10 melanoma cells [1]. In MKN-45, 1 μM of foretinib inhibited phosphorylation of MET and downstream signaling molecules. Further, 1 μM of foretinib inhibited phosphorylation of FGFR2 and downstream molecules, suggesting that foretinib targets FGFR2 in KATO-III. Foretinib inhibits phosphorylation of epidermal growth factor receptor (EGFR), HER3 and FGFR3 via MET inhibition in MKN-45, and EGFR, HER3 and MET via FGFR2 inhibition in KATO-III [2].
In vivo A single 100 mg/kg oral gavage dose of EXEL-2880 resulted in substantial inhibition of phosphorylation of B16F10 tumor Met, which persisted through 24 h. Once daily oral gavage administration of EXEL-2880 resulted in a dose-dependent reduction in tumor burden of 31% and 62%, respectively, for doses of 30 and 100 mg/kg. The lung surface tumor burden, calculated by multiplying the total nodule count by the average nodule diameter for each tumor, was reduced by 50% and 58% following treatment with 30 and 100 mg/kg EXEL-2880, respectively [1]. The daily oral administration of foretinib (30 mg/kg) significantly inhibited the growth of tumor in all three of the tumor xenografts starting after only seven days of administration, and lasting throughout the experiment. Moreover, TEN cell tumor xenografts completely vanished in all specimens after 14 days of foretinib treatment [3].
Kinase Assay Kinase inhibition was investigated using one of three assay formats: [33P]phosphoryl transfer, luciferase-coupled chemiluminescence, or AlphaScreen tyrosine kinase technology. Further assay details are provided in Supplementary Section. IC50 values were calculated by nonlinear regression analysis using XLFit [1].
Cell Research PC-3 and B16F10 cells were seeded in 24-well plates overnight. The cells were then washed and incubated with serum-free medium for 3 h followed by a 1 h incubation with EXEL-2880 before addition of HGF (100 ng/mL) for 10 min. Met phosphorylation status was determined by ELISA analysis (Supplementary Data). For determination of VEGF-stimulated extracellular signal-regulated kinase phosphorylation, human umbilical vein endothelial cells were seeded in 96-well plates and incubated for 24 h and then serum-starved for another 24 h. A serial dilution of EXEL-2880 was added for 1 h before a 5 min stimulation with VEGF (20 ng/mL). Medium was removed, and the cells were fixed with Cytofix and then treated with 0.6% H2O2. Plates were blocked with 10% FBS and incubated with a mouse monoclonal anti-phosphorylated extracellular signal-regulated kinase p44/42 antibody (E10) followed by incubation with goat anti-mouse IgG-horseradish peroxidase and chemiluminescent detection. IC50 values were calculated based on triplicate experiments [1].
Animal Research B16F10 tumor cells (2 × 10^5) were implanted via i.v. tail vein injection into mice on day 0. EXEL-2880 or vehicle administration was initiated 3 days after implantation for 10 days followed by assessment of lung tumor burden. Lungs were excised, weighed, and zinc-fixed for 24 h, and the number of nodules formed on all lobe surfaces was counted using a Zeiss stereoscope. Lung nodule diameters were morphometrically measured on digitally captured images. Inhibition of tumor burden as measured by lung wet weight was calculated as follows: % tumor growth inhibition = [(compound treated-naive / vehicle-naive) × 100]. The results for each treatment group (n = 10 animals) were averaged, and statistical t test analysis was done comparing each treatment group to the vehicle-treated control [1].
Synonyms GSK089, EXEL-2880, GSK1363089, XL880
Molecular Weight 632.65
Formula C34H34F2N4O6
CAS No. 849217-64-7

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Solubility Information

Ethanol: 63.3 mg/mL (100 mM)

DMSO: 63.3 mg/mL (100 mM)

TargetMolReferences and Literature

1. Qian F, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res, 2009, 69(20), 8009-8016. 2. Kataoka Y, et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs, 2011. 3. Kogata Y, et al. Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer. Oncotarget. 2018 Apr 27;9(32):22769-22784.

TargetMolCitations

1. Wang P, Zhang Y, Xiang R, et al.Foretinib is effective in acute myeloid leukemia by inhibiting FLT3 and overcoming secondary mutations that drive resistance to quizartinib and gilteritinib.Cancer Research.2024

Related compound libraries

This product is contained In the following compound libraries:
Tyrosine Kinase Inhibitor Library Inhibitor Library Anti-Cancer Active Compound Library Anti-Cancer Clinical Compound Library Drug Repurposing Compound Library Kinase Inhibitor Library Anti-Cancer Drug Library Angiogenesis related Compound Library Immuno-Oncology Compound Library Anti-Ovarian Cancer Compound Library

Related Products

Related compounds with same targets
Sanguinarine chloride Tanshinone IIA NVP-ACC789 BFH772 TG 100801 Hydrochloride AG-13958 Jaceidin A-443654

TargetMolDose Conversion

You can also refer to dose conversion for different animals. More

TargetMol In vivo Formulation Calculator (Clear solution)

Step One: Enter information below
Dosage
mg/kg
Average weight of animals
g
Dosing volume per animal
ul
Number of animals
Step Two: Enter the in vivo formulation
% DMSO
%
% Tween 80
% ddH2O
Calculate Reset

TargetMolCalculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculation
Molecular Weight Calculator
=
X
X

Molarity Calculator allows you to calculate the

  • Mass of a compound required to prepare a solution of known volume and concentration
  • Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Concentration of a solution resulting from a known mass of compound in a specific volume
See Example

An example of a molarity calculation using the molarity calculator
What is the mass of compound required to make a 10 mM stock solution in 10 ml of water given that the molecular weight of the compound is 197.13 g/mol?
Enter 197.13 into the Molecular Weight (MW) box
Enter 10 into the Concentration box and select the correct unit (millimolar)
Enter 10 into the Volume box and select the correct unit (milliliter)
Press calculate
The answer of 19.713 mg appears in the Mass box

X
=
X

Calculator the dilution required to prepare a stock solution

Calculate the dilution required to prepare a stock solution
The dilution calculator is a useful tool which allows you to calculate how to dilute a stock solution of known concentration. Enter C1, C2 & V2 to calculate V1.

See Example

An example of a dilution calculation using the Tocris dilution calculator
What volume of a given 10 mM stock solution is required to make 20ml of a 50 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=50 μM, V2=20 ml and V1 is the unknown:
Enter 10 into the Concentration (start) box and select the correct unit (millimolar)
Enter 50 into the Concentration (final) box and select the correct unit (micromolar)
Enter 20 into the Volume (final) box and select the correct unit (milliliter)
Press calculate
The answer of 100 microliter (0.1 ml) appears in the Volume (start) box

=
/

Calculate the volume of solvent required to reconstitute your vial.

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial.
Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

g/mol

Enter the chemical formula of a compound to calculate its molar mass and elemental composition

Tip: Chemical formula is case sensitive: C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed n the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

bottom

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.

Keywords

Foretinib 849217-64-7 Angiogenesis Tyrosine Kinase/Adaptors VEGFR Tie-2 c-Met/HGFR GSK-1363089 inhibit GSK-089 GSK089 XL-880 GSK 1363089 Inhibitor EXEL-2880 GSK 089 GSK1363089 EXEL 2880 XL880 Vascular endothelial growth factor receptor EXEL2880 XL 880 inhibitor

 

TargetMol